Concepts (294)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Pulmonary Disease, Chronic Obstructive | 36 | 2019 | 3832 | 3.39 | Why? |
| alpha 1-Antitrypsin Deficiency | 4 | 2018 | 94 | 2.01 | Why? |
| Natural Language Processing | 3 | 2021 | 436 | 1.90 | Why? |
| Bronchiectasis | 2 | 2017 | 312 | 0.96 | Why? |
| Brassica | 1 | 2021 | 66 | 0.88 | Why? |
| Asthma | 10 | 2021 | 4383 | 0.81 | Why? |
| Love | 1 | 2020 | 61 | 0.80 | Why? |
| Anti-Asthmatic Agents | 3 | 2021 | 427 | 0.77 | Why? |
| Spirometry | 5 | 2018 | 524 | 0.76 | Why? |
| Accidents | 1 | 2018 | 42 | 0.74 | Why? |
| alpha 1-Antitrypsin | 3 | 2018 | 264 | 0.70 | Why? |
| Smoke-Free Policy | 1 | 2018 | 52 | 0.70 | Why? |
| Emphysema | 1 | 2018 | 52 | 0.68 | Why? |
| Pulmonary Emphysema | 2 | 2018 | 122 | 0.68 | Why? |
| Cholera | 1 | 2020 | 189 | 0.67 | Why? |
| Electronic Health Records | 2 | 2020 | 3492 | 0.67 | Why? |
| Bronchodilator Agents | 4 | 2018 | 444 | 0.65 | Why? |
| Smoking | 9 | 2018 | 3358 | 0.63 | Why? |
| Music | 1 | 2018 | 107 | 0.61 | Why? |
| Singing | 1 | 2018 | 143 | 0.61 | Why? |
| Forced Expiratory Volume | 9 | 2018 | 632 | 0.61 | Why? |
| Machine Learning | 3 | 2021 | 4395 | 0.60 | Why? |
| Global Burden of Disease | 2 | 2019 | 531 | 0.58 | Why? |
| Population Density | 1 | 2020 | 694 | 0.56 | Why? |
| Spain | 21 | 2021 | 15545 | 0.50 | Why? |
| Smoking Cessation | 2 | 2018 | 826 | 0.46 | Why? |
| Smokers | 1 | 2017 | 550 | 0.45 | Why? |
| Clinical Audit | 3 | 2018 | 204 | 0.38 | Why? |
| Mass Screening | 2 | 2020 | 8005 | 0.38 | Why? |
| Physician's Role | 1 | 2018 | 853 | 0.37 | Why? |
| Noncommunicable Diseases | 1 | 2018 | 934 | 0.37 | Why? |
| Delayed Diagnosis | 1 | 2017 | 1529 | 0.33 | Why? |
| Personnel, Hospital | 1 | 2020 | 2273 | 0.33 | Why? |
| Sex Factors | 3 | 2020 | 11014 | 0.32 | Why? |
| Biological Products | 1 | 2021 | 2331 | 0.32 | Why? |
| Medical Audit | 2 | 2017 | 218 | 0.31 | Why? |
| Age of Onset | 2 | 2018 | 557 | 0.30 | Why? |
| Mortality | 2 | 2020 | 7132 | 0.28 | Why? |
| Mobile Applications | 1 | 2020 | 3032 | 0.28 | Why? |
| Lung Neoplasms | 2 | 2019 | 3228 | 0.27 | Why? |
| Th2 Cells | 2 | 2018 | 680 | 0.26 | Why? |
| Sex Distribution | 3 | 2020 | 2083 | 0.26 | Why? |
| Primary Health Care | 4 | 2019 | 4839 | 0.26 | Why? |
| Bias | 2 | 2021 | 1109 | 0.26 | Why? |
| Population Surveillance | 1 | 2020 | 4967 | 0.26 | Why? |
| Communicable Diseases | 1 | 2018 | 2148 | 0.25 | Why? |
| Pulmonary Medicine | 3 | 2019 | 706 | 0.25 | Why? |
| Pneumonia | 2 | 2020 | 5652 | 0.24 | Why? |
| Humans | 66 | 2021 | 930598 | 0.24 | Why? |
| Coronary Artery Disease | 1 | 2017 | 2570 | 0.24 | Why? |
| Outpatient Clinics, Hospital | 2 | 2017 | 523 | 0.23 | Why? |
| Vital Capacity | 3 | 2018 | 399 | 0.23 | Why? |
| Antigens, CD1 | 1 | 2020 | 31 | 0.22 | Why? |
| Masks | 2 | 2020 | 8528 | 0.22 | Why? |
| Adrenal Cortex Hormones | 6 | 2019 | 6537 | 0.21 | Why? |
| Hospitals | 1 | 2020 | 11793 | 0.21 | Why? |
| Male | 40 | 2021 | 367725 | 0.21 | Why? |
| Myocardial Ischemia | 2 | 2017 | 781 | 0.21 | Why? |
| Female | 40 | 2021 | 380317 | 0.20 | Why? |
| Middle Aged | 35 | 2021 | 270681 | 0.20 | Why? |
| Epidemics | 1 | 2020 | 6407 | 0.20 | Why? |
| Intensive Care Units | 3 | 2021 | 29594 | 0.20 | Why? |
| Health Care Costs | 2 | 2018 | 1007 | 0.20 | Why? |
| Aged | 32 | 2021 | 215776 | 0.19 | Why? |
| Lung | 7 | 2020 | 31049 | 0.19 | Why? |
| Tetraodontiformes | 1 | 2018 | 3 | 0.19 | Why? |
| Quality-Adjusted Life Years | 2 | 2019 | 511 | 0.19 | Why? |
| Selection Bias | 1 | 2019 | 201 | 0.19 | Why? |
| Telemedicine | 3 | 2020 | 25032 | 0.18 | Why? |
| Nutrition Disorders | 1 | 2018 | 37 | 0.18 | Why? |
| Mandibular Advancement | 1 | 2017 | 5 | 0.18 | Why? |
| Vegetables | 1 | 2021 | 340 | 0.18 | Why? |
| Peak Expiratory Flow Rate | 1 | 2018 | 64 | 0.18 | Why? |
| Fluticasone-Salmeterol Drug Combination | 1 | 2017 | 10 | 0.18 | Why? |
| Disease Progression | 6 | 2018 | 13580 | 0.18 | Why? |
| History, 16th Century | 1 | 2018 | 104 | 0.18 | Why? |
| Androstadienes | 1 | 2017 | 27 | 0.18 | Why? |
| Otitis Media | 1 | 2019 | 106 | 0.17 | Why? |
| Pulmonary Eosinophilia | 1 | 2017 | 46 | 0.17 | Why? |
| History, 17th Century | 1 | 2018 | 172 | 0.17 | Why? |
| History, 18th Century | 1 | 2018 | 192 | 0.17 | Why? |
| Back Pain | 1 | 2018 | 115 | 0.17 | Why? |
| Maxilla | 1 | 2017 | 70 | 0.17 | Why? |
| Neck Pain | 1 | 2018 | 126 | 0.16 | Why? |
| Ethanolamines | 1 | 2017 | 71 | 0.16 | Why? |
| Prognosis | 8 | 2021 | 32490 | 0.16 | Why? |
| Cell Movement | 1 | 2020 | 695 | 0.16 | Why? |
| Ambulatory Care | 3 | 2018 | 4947 | 0.16 | Why? |
| Time Factors | 6 | 2020 | 31397 | 0.16 | Why? |
| Interleukin-13 | 1 | 2018 | 204 | 0.16 | Why? |
| Haemophilus influenzae | 1 | 2017 | 196 | 0.16 | Why? |
| Follow-Up Studies | 4 | 2018 | 17020 | 0.16 | Why? |
| Markov Chains | 1 | 2018 | 502 | 0.16 | Why? |
| Tobacco Smoke Pollution | 1 | 2019 | 181 | 0.16 | Why? |
| Diagnostic Errors | 3 | 2017 | 865 | 0.15 | Why? |
| European Union | 1 | 2020 | 565 | 0.15 | Why? |
| History, 19th Century | 1 | 2018 | 384 | 0.15 | Why? |
| Disclosure | 1 | 2020 | 423 | 0.15 | Why? |
| Pneumonia, Viral | 6 | 2020 | 243684 | 0.15 | Why? |
| Glycoproteins | 1 | 2020 | 615 | 0.15 | Why? |
| Coronavirus Infections | 6 | 2020 | 253789 | 0.15 | Why? |
| Network Meta-Analysis | 1 | 2017 | 426 | 0.15 | Why? |
| Airway Obstruction | 1 | 2017 | 182 | 0.14 | Why? |
| Surgery, Computer-Assisted | 1 | 2017 | 183 | 0.14 | Why? |
| Cause of Death | 3 | 2018 | 4823 | 0.14 | Why? |
| Inappropriate Prescribing | 1 | 2018 | 284 | 0.14 | Why? |
| Tandem Mass Spectrometry | 1 | 2021 | 1031 | 0.14 | Why? |
| Body Temperature | 1 | 2020 | 875 | 0.14 | Why? |
| Medical Overuse | 1 | 2017 | 146 | 0.14 | Why? |
| Eosinophils | 2 | 2018 | 848 | 0.14 | Why? |
| Forecasting | 2 | 2020 | 4492 | 0.14 | Why? |
| Phenotype | 4 | 2018 | 4037 | 0.14 | Why? |
| Health Resources | 2 | 2018 | 2592 | 0.14 | Why? |
| Eosinophilia | 1 | 2017 | 292 | 0.14 | Why? |
| Infant, Newborn, Diseases | 1 | 2018 | 394 | 0.13 | Why? |
| Kaplan-Meier Estimate | 3 | 2018 | 4260 | 0.13 | Why? |
| United Kingdom | 6 | 2020 | 18046 | 0.13 | Why? |
| Europe | 3 | 2020 | 12702 | 0.13 | Why? |
| Altitude | 1 | 2017 | 311 | 0.13 | Why? |
| Geographic Information Systems | 1 | 2017 | 507 | 0.13 | Why? |
| Accidents, Traffic | 1 | 2018 | 464 | 0.13 | Why? |
| Adult | 16 | 2021 | 244371 | 0.13 | Why? |
| Cohort Studies | 9 | 2019 | 36005 | 0.12 | Why? |
| Quarantine | 1 | 2020 | 18418 | 0.12 | Why? |
| Hospitalization | 2 | 2020 | 54280 | 0.12 | Why? |
| Switzerland | 1 | 2020 | 2738 | 0.12 | Why? |
| Sputum | 2 | 2017 | 1720 | 0.11 | Why? |
| Spatial Analysis | 1 | 2017 | 878 | 0.11 | Why? |
| Disease Outbreaks | 1 | 2020 | 27595 | 0.11 | Why? |
| Age Distribution | 2 | 2018 | 3567 | 0.11 | Why? |
| History, 20th Century | 1 | 2018 | 1282 | 0.11 | Why? |
| Heart | 1 | 2021 | 1791 | 0.11 | Why? |
| Communicable Disease Control | 1 | 2020 | 29620 | 0.11 | Why? |
| Disabled Persons | 2 | 2019 | 1152 | 0.11 | Why? |
| History, 21st Century | 1 | 2018 | 1849 | 0.10 | Why? |
| Bronchi | 1 | 2017 | 1048 | 0.10 | Why? |
| Survival Rate | 3 | 2020 | 9206 | 0.10 | Why? |
| Sleep Apnea, Obstructive | 1 | 2017 | 668 | 0.09 | Why? |
| Pilot Projects | 1 | 2020 | 5182 | 0.09 | Why? |
| Aged, 80 and over | 8 | 2020 | 88759 | 0.09 | Why? |
| Medication Adherence | 1 | 2018 | 1270 | 0.09 | Why? |
| Monocytes | 1 | 2020 | 2978 | 0.09 | Why? |
| Guideline Adherence | 2 | 2017 | 2309 | 0.09 | Why? |
| Pandemics | 6 | 2020 | 389249 | 0.08 | Why? |
| Cost-Benefit Analysis | 1 | 2017 | 2259 | 0.08 | Why? |
| Weight Loss | 1 | 2013 | 826 | 0.08 | Why? |
| Severity of Illness Index | 7 | 2020 | 48226 | 0.08 | Why? |
| Dyspnea | 1 | 2020 | 3847 | 0.08 | Why? |
| Monitoring, Physiologic | 1 | 2018 | 1956 | 0.08 | Why? |
| Terminal Care | 1 | 2017 | 928 | 0.08 | Why? |
| Retrospective Studies | 5 | 2021 | 105322 | 0.08 | Why? |
| Health Status | 1 | 2020 | 3259 | 0.08 | Why? |
| Drug Therapy, Combination | 2 | 2018 | 7268 | 0.08 | Why? |
| Home Care Services | 1 | 2018 | 1351 | 0.08 | Why? |
| Tuberculosis, Pulmonary | 1 | 2017 | 1171 | 0.08 | Why? |
| Inflammation Mediators | 1 | 2018 | 2654 | 0.08 | Why? |
| Practice Guidelines as Topic | 4 | 2018 | 15421 | 0.08 | Why? |
| Respiratory Function Tests | 3 | 2018 | 1755 | 0.08 | Why? |
| Cross-Sectional Studies | 9 | 2018 | 53120 | 0.08 | Why? |
| Prevalence | 8 | 2019 | 25773 | 0.07 | Why? |
| Interleukin-6 | 2 | 2020 | 7522 | 0.07 | Why? |
| Treatment Outcome | 7 | 2020 | 51732 | 0.07 | Why? |
| Young Adult | 3 | 2021 | 93724 | 0.07 | Why? |
| Disease Management | 3 | 2018 | 6841 | 0.07 | Why? |
| Emergency Service, Hospital | 2 | 2020 | 14232 | 0.07 | Why? |
| Administration, Inhalation | 3 | 2018 | 1647 | 0.07 | Why? |
| Quality Improvement | 1 | 2017 | 2435 | 0.07 | Why? |
| Prospective Studies | 5 | 2021 | 43301 | 0.07 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.07 | Why? |
| Latin America | 2 | 2021 | 1721 | 0.06 | Why? |
| Symptom Assessment | 1 | 2017 | 4967 | 0.06 | Why? |
| Surveys and Questionnaires | 4 | 2019 | 43792 | 0.06 | Why? |
| Risk Factors | 5 | 2018 | 71621 | 0.06 | Why? |
| Databases, Factual | 1 | 2018 | 6248 | 0.06 | Why? |
| Patient Acceptance of Health Care | 2 | 2018 | 5002 | 0.06 | Why? |
| Incidence | 3 | 2019 | 25622 | 0.06 | Why? |
| Obesity, Morbid | 1 | 2013 | 1340 | 0.06 | Why? |
| Palliative Care | 1 | 2017 | 2665 | 0.06 | Why? |
| Biomedical Research | 2 | 2019 | 5270 | 0.06 | Why? |
| Adolescent | 3 | 2021 | 86841 | 0.06 | Why? |
| Practice Patterns, Physicians' | 2 | 2018 | 4927 | 0.06 | Why? |
| Risk Assessment | 4 | 2018 | 25439 | 0.06 | Why? |
| Length of Stay | 1 | 2018 | 11042 | 0.05 | Why? |
| Algorithms | 1 | 2017 | 7346 | 0.05 | Why? |
| Infant, Newborn | 2 | 2019 | 23105 | 0.05 | Why? |
| Life Style | 1 | 2013 | 2708 | 0.05 | Why? |
| West Indies | 1 | 2018 | 48 | 0.05 | Why? |
| Central America | 1 | 2018 | 86 | 0.05 | Why? |
| Case-Control Studies | 1 | 2018 | 17671 | 0.05 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 9335 | 0.05 | Why? |
| Electrooculography | 1 | 2017 | 6 | 0.05 | Why? |
| Comorbidity | 3 | 2017 | 34796 | 0.05 | Why? |
| Cephalometry | 1 | 2017 | 41 | 0.04 | Why? |
| Sickness Impact Profile | 1 | 2017 | 56 | 0.04 | Why? |
| Discriminant Analysis | 1 | 2018 | 170 | 0.04 | Why? |
| Interleukin-5 | 1 | 2018 | 138 | 0.04 | Why? |
| Respiratory Tract Infections | 1 | 2019 | 6817 | 0.04 | Why? |
| Fluticasone | 1 | 2017 | 65 | 0.04 | Why? |
| Geographic Mapping | 1 | 2018 | 247 | 0.04 | Why? |
| Leukocyte Count | 2 | 2017 | 3178 | 0.04 | Why? |
| Formoterol Fumarate | 1 | 2017 | 61 | 0.04 | Why? |
| Phosphodiesterase Inhibitors | 1 | 2017 | 61 | 0.04 | Why? |
| Expectorants | 1 | 2017 | 95 | 0.04 | Why? |
| Registries | 1 | 2017 | 12327 | 0.04 | Why? |
| South America | 1 | 2018 | 565 | 0.04 | Why? |
| Diagnostic Techniques, Respiratory System | 1 | 2017 | 114 | 0.04 | Why? |
| Sensitivity and Specificity | 1 | 2018 | 22971 | 0.04 | Why? |
| Sampling Studies | 1 | 2017 | 386 | 0.04 | Why? |
| Pulmonologists | 1 | 2017 | 98 | 0.04 | Why? |
| Decision Trees | 1 | 2018 | 441 | 0.04 | Why? |
| Bronchitis | 1 | 2017 | 146 | 0.04 | Why? |
| Polysomnography | 1 | 2017 | 296 | 0.04 | Why? |
| Electromyography | 1 | 2017 | 278 | 0.04 | Why? |
| Multivariate Analysis | 2 | 2017 | 5440 | 0.04 | Why? |
| Disease-Free Survival | 1 | 2020 | 1654 | 0.04 | Why? |
| Serum Albumin, Human | 1 | 2017 | 265 | 0.04 | Why? |
| Cell Adhesion Molecules | 1 | 2018 | 472 | 0.04 | Why? |
| Random Allocation | 1 | 2017 | 773 | 0.03 | Why? |
| Data Accuracy | 1 | 2020 | 715 | 0.03 | Why? |
| Chemoprevention | 1 | 2019 | 585 | 0.03 | Why? |
| Chi-Square Distribution | 1 | 2017 | 961 | 0.03 | Why? |
| North America | 1 | 2018 | 1400 | 0.03 | Why? |
| Immunoglobulin E | 1 | 2017 | 557 | 0.03 | Why? |
| Oxygen Inhalation Therapy | 2 | 2018 | 3629 | 0.03 | Why? |
| Argentina | 1 | 2017 | 1141 | 0.03 | Why? |
| Interleukin-17 | 1 | 2018 | 602 | 0.03 | Why? |
| Colombia | 1 | 2017 | 1241 | 0.03 | Why? |
| New York | 1 | 2020 | 2488 | 0.03 | Why? |
| Predictive Value of Tests | 2 | 2017 | 9537 | 0.03 | Why? |
| Imaging, Three-Dimensional | 1 | 2017 | 680 | 0.03 | Why? |
| Quality of Life | 3 | 2017 | 9820 | 0.03 | Why? |
| Reproducibility of Results | 2 | 2020 | 11304 | 0.03 | Why? |
| Syndrome | 1 | 2017 | 1310 | 0.03 | Why? |
| Interleukin-8 | 1 | 2018 | 964 | 0.03 | Why? |
| Dendritic Cells | 1 | 2020 | 1330 | 0.03 | Why? |
| Hospitals, Public | 1 | 2018 | 774 | 0.03 | Why? |
| Exercise Tolerance | 1 | 2017 | 634 | 0.03 | Why? |
| Motor Activity | 1 | 2013 | 217 | 0.03 | Why? |
| Logistic Models | 2 | 2017 | 9089 | 0.03 | Why? |
| Belgium | 1 | 2017 | 2064 | 0.03 | Why? |
| National Health Programs | 1 | 2018 | 807 | 0.03 | Why? |
| Global Health | 3 | 2019 | 13911 | 0.03 | Why? |
| Neoplasms | 1 | 2019 | 17251 | 0.03 | Why? |
| Regression Analysis | 1 | 2018 | 2484 | 0.03 | Why? |
| Respiratory Therapy | 1 | 2018 | 918 | 0.03 | Why? |
| Delivery of Health Care | 1 | 2017 | 15909 | 0.03 | Why? |
| Electroencephalography | 1 | 2017 | 1242 | 0.03 | Why? |
| Behavior Therapy | 1 | 2013 | 235 | 0.03 | Why? |
| Nitric Oxide | 1 | 2017 | 769 | 0.03 | Why? |
| Area Under Curve | 1 | 2017 | 2564 | 0.02 | Why? |
| Biomarkers | 3 | 2018 | 23361 | 0.02 | Why? |
| Survival Analysis | 2 | 2017 | 7592 | 0.02 | Why? |
| Cluster Analysis | 1 | 2017 | 3001 | 0.02 | Why? |
| Hypersensitivity | 1 | 2019 | 1137 | 0.02 | Why? |
| Nutrition Assessment | 1 | 2013 | 527 | 0.02 | Why? |
| Animals | 1 | 2018 | 78931 | 0.02 | Why? |
| Environmental Exposure | 1 | 2019 | 1558 | 0.02 | Why? |
| Tumor Necrosis Factor-alpha | 1 | 2018 | 2483 | 0.02 | Why? |
| Drug Combinations | 1 | 2017 | 3852 | 0.02 | Why? |
| Urban Population | 1 | 2017 | 2000 | 0.02 | Why? |
| Antioxidants | 1 | 2017 | 1593 | 0.02 | Why? |
| Counseling | 1 | 2013 | 747 | 0.02 | Why? |
| Health Surveys | 1 | 2017 | 2841 | 0.02 | Why? |
| Lung Diseases | 1 | 2019 | 2361 | 0.02 | Why? |
| Risk | 1 | 2018 | 5288 | 0.02 | Why? |
| Glycated Hemoglobin A | 1 | 2013 | 1316 | 0.02 | Why? |
| ROC Curve | 1 | 2017 | 6024 | 0.02 | Why? |
| Randomized Controlled Trials as Topic | 2 | 2019 | 10649 | 0.02 | Why? |
| Germany | 1 | 2020 | 9196 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2017 | 6543 | 0.02 | Why? |
| Body Mass Index | 1 | 2017 | 4306 | 0.02 | Why? |
| Evidence-Based Medicine | 1 | 2017 | 3228 | 0.02 | Why? |
| International Cooperation | 1 | 2017 | 3436 | 0.02 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2020 | 5837 | 0.02 | Why? |
| Research Design | 1 | 2019 | 5830 | 0.02 | Why? |
| Models, Statistical | 1 | 2020 | 5312 | 0.01 | Why? |
| Diagnosis, Differential | 1 | 2017 | 7220 | 0.01 | Why? |
| Bariatric Surgery | 1 | 2013 | 1298 | 0.01 | Why? |
| Blood Pressure | 1 | 2013 | 2198 | 0.01 | Why? |
| Tuberculosis | 1 | 2017 | 2895 | 0.01 | Why? |
| France | 1 | 2017 | 12074 | 0.01 | Why? |
| Societies, Medical | 1 | 2017 | 6907 | 0.01 | Why? |
| Referral and Consultation | 1 | 2017 | 4816 | 0.01 | Why? |
| Patient Admission | 1 | 2017 | 5250 | 0.01 | Why? |
| Socioeconomic Factors | 1 | 2017 | 8495 | 0.01 | Why? |
| Blood Glucose | 1 | 2013 | 3642 | 0.01 | Why? |
| Age Factors | 1 | 2017 | 21039 | 0.01 | Why? |
| Infant | 1 | 2019 | 30274 | 0.01 | Why? |
| Italy | 1 | 2020 | 38444 | 0.01 | Why? |
| Anti-Bacterial Agents | 1 | 2017 | 10083 | 0.01 | Why? |
| Child, Preschool | 1 | 2019 | 36283 | 0.01 | Why? |
| United States | 1 | 2018 | 46150 | 0.01 | Why? |
| Tomography, X-Ray Computed | 1 | 2017 | 25144 | 0.01 | Why? |
| Child | 1 | 2019 | 70012 | 0.01 | Why? |